Pharming, Santarus submit angioedema drug for FDA approval

04/18/2013 | Pharmaceutical Business Review Online

Pharming Group and Santarus have filed a biologics license application with the FDA for approval to use Ruconest, a recombinant human C1 esterase inhibitor, as a treatment for acute angioedema attacks in people with hereditary angioedema. Santarus holds the right to market the drug in North America.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX